14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today BIOC ranks #20757 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$2.86 (-1.72%)

Volume: 167k

Closed: Jan 26, 2022

Hollow Logo Score: -7.305

Biocept Stock Forecast

$2.86 (-1.72%)

Volume: 167k

Closed: Jan 26, 2022

Score Hollow Logo -7.305

Biocept Company Profile

5810 Nancy Ridge Drive

San Diego CA 92121





Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide an information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. It offers assays for solid tumor indications, such as breast cancer, lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE